Chou A, et al. - In patients with pancreatic neuroendocrine tumors (PanNET), researchers evaluated the clinical significance of the loss of the ATRX (alpha-thalassemia/mental retardation syndrome X-linked) and DAXX (death domain-associated protein) proteins, as verified by immunohistochemistry (IHC). Findings from the present study suggest that loss of expression of ATRX was valuable in independently predicting poor overall survival in PanNETs. It was noted that ATRX loss might have a role in routine clinical practice to refine prognostication in patients with PanNET, given its relative availability.